Core Viewpoint - The financial reports of major chain pharmacy companies in A-shares indicate a challenging environment, with only one company, Yifeng Pharmacy, showing profit growth in 2024, while others faced declines, highlighting the difficulties of relying solely on store expansion for growth [1][3]. Financial Performance - In 2024, Yifeng Pharmacy achieved a revenue of 24.06 billion yuan, a year-on-year increase of 6.53%, and a net profit of 1.529 billion yuan, up 8.26% [4]. - In contrast, Shuyu Pingmin reported a revenue of 9.57 billion yuan, a 4.13% increase, but a net loss of 189 million yuan, marking a 241.9% decline compared to the previous year [3][4]. - Other companies like Laobaixing and Yixin Tang also experienced revenue declines, with Laobaixing's revenue at 22.358 billion yuan, down 0.36%, and a net profit decrease of 44.13% [4]. Store Expansion and Closure - Despite the financial struggles, the number of stores for the six major companies continued to grow in 2024, with Yifeng Pharmacy adding 2,512 stores, resulting in a total of 14,684 stores [5]. - Laobaixing reported a total of 15,277 stores, with a net increase of 1,703 stores during the year [6]. - However, the closure rate also increased, with Daclin closing 733 stores due to strategic adjustments [6]. Industry Challenges - The industry is facing significant challenges, including intensified competition, rising costs, and changing consumer purchasing habits, which are reflected in the declining net profits of listed chain pharmacies [4][8]. - The adjustment of medical insurance policies has also impacted the performance of chain pharmacies, leading to a shift in consumer purchasing behavior and a decrease in foot traffic to physical stores [8][9]. Future Directions - Experts suggest that the future development of chain pharmacies should focus on high-quality services rather than mere expansion, as the market becomes saturated [7]. - Companies are encouraged to enhance operational efficiency and improve service quality to remain competitive in a challenging environment [7][9].
“跑马圈地”后遗症显现,上市连锁药店迎业绩寒冬